Shares of Merck & Co. Inc. fell more than 0.5% on Monday afternoon, tracking their fifth consecutive decline in the worst ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc.

During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...